1. Natural antibodies:Protecting role of IgM in glioblastoma and brain tumours
- Author
-
Julie Bouckaert, Rabah Boukherroub, Savvas N. Savvides, Shubham Semwal, Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF], NanoBioInterfaces - IEMN [NBI - IEMN], Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 [IEMN], Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF], Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 (UGSF), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 (IEMN), Centrale Lille-Institut supérieur de l'électronique et du numérique (ISEN)-Université de Valenciennes et du Hainaut-Cambrésis (UVHC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF), Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 (UGSF), The authors acknowledge financial support through the Programme for EArly-stage Researchers in Lille (PEARL), under the auspices of the European Union Horizon 2020 research and innovation programme, project 'ATACA' with Marie Sklodowska-Curie agreement No. 847568. PEARL is coordinated by the Foundation I-SITE ULNE and implemented at the Centre National de la Recherche Scientific (CNRS), European Project: 847568,H2020,H2020-MSCA-COFUND-2018,PEARL(2019), Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), NanoBioInterfaces - IEMN (NBI - IEMN), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA)-Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Institut National de la Recherche Agronomique (INRA)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Programme for EArly-stage Researchers in Lille (PEARL), under the auspices of the European Union Horizon 2020 research and innovation programmeproject 'ATACA' with Marie Sklodowska-Curie agreement No. 847568. PEARL is coordinated by the Foundation I-SITE ULNE and implemented at the Centre National de la Recherche Scientific (CNRS)., Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL)-Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Universiteit Gent = Ghent University [Belgium] (UGENT), Université de Lille, CNRS, Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) - UMR 8576, and Institut d'Électronique, de Microélectronique et de Nanotechnologie (IEMN) - UMR 8520
- Subjects
Oncology ,MONOCLONAL-ANTIBODY ,medicine.medical_treatment ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,[SDV]Life Sciences [q-bio] ,microglia ,Disease ,01 natural sciences ,IgM ,Glioblastoma ,Natural Antibodies ,Immunotherapy ,Microglia ,ALK ,PHASE-I TRIAL ,Drug Discovery ,Medicine and Health Sciences ,Tumor Microenvironment ,Medicine ,0303 health sciences ,biology ,BARRIER DISRUPTION ,Brain Neoplasms ,Standard treatment ,Astrocytoma ,3. Good health ,[CHIM.THEO]Chemical Sciences/Theoretical and/or physical chemistry ,B-CELLS ,GLIOMA ,immunotherapy ,Antibody ,medicine.medical_specialty ,MEDLINE ,PEPTIDE-VACCINE ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,natural antibodies ,Internal medicine ,Humans ,CANCER-CELLS ,030304 developmental biology ,Pharmacology ,RECEPTOR ,business.industry ,glioblastoma ,Cancer ,Biology and Life Sciences ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,medicine.disease ,IMMUNE SURVEILLANCE ,LIPID-A ANTIBODY ,0104 chemical sciences ,nervous system diseases ,010404 medicinal & biomolecular chemistry ,Immunoglobulin M ,biology.protein ,business - Abstract
Background: Glioblastoma is a grade IV astrocytoma with an average survival span for patients of 18 months after initial diagnosis and no standard treatment protocol is available. Therefore, there is a need to search for novel approaches to target glioblastoma. Objectives: This review intends to capture the role of immunoglobulin-M in cancer, more specifically in glioblastoma multiforme (GBM), and to compile the latest developments and immunological pathways relevant to glioblastoma. Methods: Information on glioblastoma, cancer microenvironment, cancer therapeutics, and how to improve the scenario were obtained from scientific literature databases such as Pubmed, Medline, Google Scholar, Science Direct, Springer, Wiley online library, and some data was harvested from regulatory and compliance databases such as clinicaltrials.gov, FDA database, and WHO Globocan. Results and Conclusions: Currently, only a limited number of therapies are approved for GBM, and no standard care is in place in case of disease relapse, necessitating a possible broader perspective in looking at the disease and its underlying mechanisms.
- Published
- 2021
- Full Text
- View/download PDF